Literature DB >> 16054967

Cervical squamous intraepithelial lesions of low-grade in HIV-infected women: recurrence, persistence, and progression, in treated and untreated women.

L Nappi1, C Carriero, S Bettocchi, J Herrero, A Vimercati, G Putignano.   

Abstract

BACKGROUND: Human immunodeficiency virus (HIV)-infected patients are more predisposed than HIV-negative women to develop squamous intraepithelial lesions (SIL) of the uterine cervix, and cervical dysplasia may be of higher grade in HIV-positive women than in HIV-negative subjects, with more extensive and multi-centric involvement of the lower genital tract by human papillomavirus (HPV)-associated lesions. Moreover, recurrence and progression rate of cervical intraepithelial neoplasia (CIN) is particularly higher in immunocompromised women.
DESIGN: Retrospective case-control study of HIV-positive women and HIV-negative controls, all affected by low-grade SIL of the uterine cervix, treated by loop excision or followed-up without treatment. Correlation of progression and recurrence of SIL with HIV status and CD4+ count. PATIENTS: From September 1990 to October 1997, 75 HIV-positive low-grade-SIL patients, 47 treated and 28 followed-up without treatment, and 75 HIV-negative low-grade-SIL controls, 45 treated and 30 followed-up.
RESULTS: Among treated patients, 17/47 (36.2%) HIV-positive and 5/45 (11.1%) controls had recurrence (P < 0.0101, O.R. = 4.53, 95% CI = 1.5-13.7), progression of untreated lesion was seen in 15/28 (53.6%) HIV-positive and 7/30 (23%) controls (P < 0.05, O.R. = 3.79, 95% CI = 1.23-11.69). The risk of recurrence or progression of low-grade SIL linked to HIV seropositivity is about 4-5 times higher in comparison with seronegative counterpart, matched for age, risk factors and lesion size. More significantly, considering the cut-off of 200 CD4+/mm(3) in HIV-positive women, 13/17 cases of recurrence (P < 0.05, O.R. = 4.88, 95% CI = 1.28-18.58) and 10/15 cases with progression (P < 0.05, O.R. = 6.67, 95% CI = 1.24-35.73) were immunocompromised (<200 CD4+/mm3), with a significant higher risk of recurrence or progression linked to immunodeficiency status. Considering time of progression or recurrence, during follow-up, Kaplan-Meier curves shows that HIV-positive status and immunodeficiency are correlated with more rapid evolution of cervical dysplasia and HPV-related lesions: comparison of recurrence in treated patients report P < 0.005 and progression in untreated P<0.05 (Mantel-Haenszel log-rank test).
CONCLUSIONS: Immunological status seems to be a determinant factor in prognosis of cervical SIL, HIV-positive women affected by this lesion, even if low-grade, need more aggressive management than the immunocompetent counterpart. Strict cytologic and colposcopic screening is recommended and CD4+ count and HPV-DNA testing may be useful risk indicators. Excisional procedures are preferred, while ablative treatments or wait and see policy may expose to some risk this type of population with poor compliance to follow-up.

Entities:  

Mesh:

Year:  2005        PMID: 16054967     DOI: 10.1016/j.ejogrb.2004.12.003

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  18 in total

1.  "My husband says this: If you are alive, you can be someone…": Facilitators and barriers to cervical cancer screening among women living with HIV in India.

Authors:  Timothy-Paul H Kung; Janna R Gordon; Asha Abdullahi; Apurva Barve; Vipul Chaudhari; Jayendrakumar K Kosambiya; Ambuj Kumar; Sukesha Gamit; Kristen J Wells
Journal:  Cancer Causes Control       Date:  2019-02-26       Impact factor: 2.506

Review 2.  [Human papilloma virus-induced disease in HIV-positive patients].

Authors:  R Wienecke; N H Brockmeyer; A Kreuter
Journal:  Hautarzt       Date:  2006-11       Impact factor: 0.751

3.  Characteristics and geographic distribution of HIV-positive women diagnosed with cervical cancer in Dar es Salaam, Tanzania.

Authors:  Kathleen Lovgren; Amr S Soliman; Twalib Ngoma; Crispin Kahesa; Jane Meza
Journal:  Int J STD AIDS       Date:  2015-10-12       Impact factor: 1.359

4.  Awareness, Knowledge and Attitudes Towards Cervical Cancer Amongst HIV-Positive Women Receiving Care in a Tertiary Hospital in Nigeria.

Authors:  Maxwell O Adibe; Deborah O Aluh
Journal:  J Cancer Educ       Date:  2018-12       Impact factor: 2.037

5.  Implementation of cervical cancer prevention services for HIV-infected women in Zambia: measuring program effectiveness.

Authors:  Groesbeck P Parham; Mulindi H Mwanahamuntu; Vikrant V Sahasrabuddhe; Andrew O Westfall; Kristin E King; Carla Chibwesha; Krista S Pfaendler; Gracilia Mkumba; Victor Mudenda; Sharon Kapambwe; Sten H Vermund; Michael L Hicks; Jeffrey Sa Stringer; Benjamin H Chi
Journal:  HIV Ther       Date:  2010

6.  Study of Prevalence of Abnormal Pap Smear and its Associated Risk Factors in HIV Positive Women: A Cross-sectional Study.

Authors:  S Prathima; B Latha; T R Ashakiran
Journal:  J Obstet Gynaecol India       Date:  2021-08-09

7.  Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine.

Authors:  Rachel Greenberg; Bruce Greenwald; J Scott Roth; Olga Ioffe; Raymond Cross
Journal:  Dig Dis Sci       Date:  2007-08-24       Impact factor: 3.199

Review 8.  Incidence and progression of cervical lesions in women with HIV: a systematic global review.

Authors:  Sheri A Denslow; Anne F Rositch; Cynthia Firnhaber; Jie Ting; Jennifer S Smith
Journal:  Int J STD AIDS       Date:  2013-08-29       Impact factor: 1.359

9.  Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination.

Authors:  Bipin N Savani; Pamela Stratton; Aarthi Shenoy; Eleftheria Kozanas; Stacey Goodman; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

10.  Early impact and performance characteristics of an established anal dysplasia screening program: program evaluation considerations.

Authors:  Christopher Mathews; Joseph Caperna; Edward R Cachay; Bard Cosman
Journal:  Open AIDS J       Date:  2007-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.